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Abstract
Background Conventional radiotherapy for painful spinal me-
tastases can be delivered with a single posterior-anterior (PA)
or two opposed anterior-posterior (APPA) fields. We studied
the effectiveness and toxicity of both techniques and studied
whether treatment technique was predictive for abdominal and
skin toxicity.
Patients and methods Within the Dutch Bone Metastasis
Study, 343 patients received 8 Gray in a single fraction or
24 Gray in six fractions for painful spinal metastases.
Treatment technique was not randomized. At baseline and
weekly during follow-up, patients reported pain and other phys-
ical complaints. Any complaint increasing within 4 weeks after
treatment was noted as a side effect. Pain response was calcu-
lated according to international standards, taking into account
changes in pain score and medication. Repeated measurement
analyses and multivariate logistic analyses were performed.
Results Patients were mainly treated on the thoracic (34%)
and lumbar (53%) spine and 73% received a PA field. Pain
response was similar between both techniques (74%). In pa-
tients treated at the thoraco-lumbar and lumbar spine, with
multiple fractions, significantly more abdominal complaints
were noticed. In multivariate analysis, radiotherapy technique
did not predict for side effects.
Conclusion Conventional radiotherapy of painful spinal me-
tastases provides limited toxicity. Radiotherapy technique is
not an independent predictor of abdominal and skin toxicity of
irradiation.
Keywords Palliative radiotherapy . Spinal metastases . Side
effects . Toxicity . Bonemetastases
Introduction
For patients with painful bone metastases, radiotherapy is an
effective treatment, with a pain response rate of more than
60%. The golden standard is to treat these patients with a
single fraction of 8 Gray (Gy) [1–3], aiming at pain relief with
minimal toxicity.
In general, side effects from this treatment are mild and
depend on factors like dose, field size, and the anatomic area
being irradiated [1, 4–6]. In several studies in patients treated
with radiotherapy for painful bone metastases, toxicity rates
between 35 and 46% are reported, consistingmainly of nausea
and/or vomiting [7–9]. A recent study in 32 patients treated for
painful bone metastases showed that over 50% of patients had
complaints of nausea and/or vomiting, despite receiving pro-
phylactic anti-emetic treatment [10].
Radiotherapy to spinal metastases can be delivered with
different treatment techniques. Highly conformal treatment
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techniques like intensity-modulated radiotherapy (IMRT) and
volumetric arc radiotherapy (VMAT) are usedmore and more,
often to higher doses. Still, frequently used conventional tech-
niques are a single posterior-anterior (PA) field or two parallel
opposed fields from anterior and posterior (APPA). The ad-
vantage of a PA field is the sparing of anterior organs like the
bowel, although the coverage of the vertebrae might be sub-
optimal [11]. By using a PA field, the dose to the posterior skin
and paraspinal musculature can be high, which can be a prob-
lem for future surgical interventions [12–14]. The advantage
of the APPA technique is a better coverage of the vertebrae
[11], while sparing the posterior skin and paraspinal muscula-
ture. A disadvantage is the higher dose in the anterior organs,
possibly leading to more abdominal side effects. In the litera-
ture, however, no prospective data on the toxicity of both
techniques have been published.
The aim of the present analysis is to study the differences in
effectiveness and toxicity of PA and APPA techniques for the
irradiation of painful spinal metastases and to identify factors
predictive for side effects of treatment. We studied patients
who received radiotherapy for painful spinal metastases with-
in the randomized Dutch Bone Metastasis Study (DBMS) [1].
Patients and methods
Details of the patient population and study protocol of the
DBMS were published elsewhere [1, 15]. In summary, the
DBMS was a nationwide, randomized trial in patients with
uncomplicated painful bone metastases. Between 1996 and
1998, a total of 1157 patients with painful bone metastases
were randomized between a single fraction (SF) of 8 or 24 Gy
in six fractions. The study showed equal effectiveness of a SF
versus multiple fractions (MF) with regard to pain response,
which was the primary endpoint. All patients provided in-
formed consent and the medical ethics committees of partici-
pating institutions approved the study.
Patients
Patients with metastases in the cervical spine were excluded
from the DBMS [1, 15]. In total, 348 patients were treated for
painful metastases in the thoracic, lumbar, or sacral spine.
Data on spinal location and treatment technique were avail-
able in 343 patients (99%). For spinal location, the treated
level of the spine (i.e., thoracic, lumbar, or sacral) was regis-
tered, without specification of the specific vertebra or verte-
brae irradiated. Treatment was performed with conventional
treatment techniques, using either a PA field or APPA fields
contributing each 50% of the total dose; no other techniques
were used. The prescription depth for PA fields was typically
at 4 to 6 cm, depending on the depth of the vertebra. The
choice for treatment technique was left to the decision of the
treating radiation oncologist and was mostly dependent on
institutional policy.
Questionnaires
At randomization and during follow-up, patients filled out 13
weekly questionnaires and monthly afterwards until 2 years of
follow-up, death, or closure of the study in December 1998.
The questionnaires consisted, among others, of the Rotterdam
Symptom Checklist (RSCL) [16], a pain scale, pain medica-
tion intake, and questions about itching and painful skin. No
data were available on the use of anti-emetics or anti-diarrhea
medication. The following items were studied to determine
toxicity: diarrhea, abdominal pain, nausea, and vomiting.
These scores were grouped into the variable Babdominal com-
plaints.^ Itching and painful skin were grouped into the vari-
able Bskin complaints.^ All items were rated on a 4-point
Likert-type scale, ranging from 1 (no complaints) to 4 (severe
complaints). To facilitate interpretation, all sum scores were
standardized to the range of 0 (no complaints) to 10 (severe
complaints). Besides sum scores, the individual item scores
were also studied. As radiotherapy of the lower spine is more
likely to affect the bowel, we studied the individual abdominal
items for the treated thoraco-lumbar, lumbar, and lumbo-
sacral vertebrae separately. Pain was measured using an 11-
point numeric rating scale, ranging from 0 (no pain) to 10 (the
worst pain imaginable). A pain score of at least 2 was required
to enter the study [1].
Statistical analyses
Pain response was calculated according to international
criteria, taking into account changes in pain medication and
pain score [17]. No fixed time interval from the date of ran-
domization was applied. A response was calculated if at least
two successive follow-up pain scores were available, which
was possible in 325 patients (95%).
To compare the categorical variables at baseline, chi-square
tests were used. To visualize and compare the course of side
effects over time, we used repeated measurement analyses
(mixed procedure), a longitudinal data analysis technique.
Analyses were also performed adjusted for treatment institute
to take into account potential confounding by indication by
institutional choice for treatment technique. p values are based
on two-sided tests and considered significant if p < 0.05.
Figures were created based on the least square means of the
repeated measurements.
To assess which baseline variables were predictive for tox-
icity, the complaints variable was dichotomized into having or
not having complaints. For that purpose, we compared the
maximal complaint scores 1 to 4 weeks after treatment with
the baseline scores. If a score was higher than the baseline
score, the patient was considered as having side effects of
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radiotherapy. The time period of 4 weeks was chosen because
by then most side effects would be present.
We applied multivariate logistic regression analyses to re-
late candidate predictors to toxicity. First, we started with a
full model, including all preselected variables. Subsequently,
we eliminated the variables by a backward selection process
with a threshold p value of 0.20, based on likelihood-ratio test
results. The chosen p value of 0.20 intends to limit the loss of
information and to select also weaker predictors, although at
the cost of including Bnoise^ variables [18]. The preselected
baseline variables, based on the literature and clinical experi-
ence, were primary tumor (breast, prostate, lung, or other can-
cer), age (≤ 65 years or > 65 years), gender (male or female),
Karnofsky performance status (KPS) [19] (≤ 60, 70–80, or
90–100), pain score (2–4, 5–7, or 8–10), presence of visceral
metastases (yes or no), concomitant systemic therapy (yes or
no), treatment arm (1 × 8 or 6 × 4 Gy), opioids (yes or no),
spinal localization (thoracic, thoraco-lumbar, lumbar, or
lumbo-sacral spine), and treatment technique (PA or APPA).
The database was analyzed using IBM SPSS statistics for
Windows version 20.0 (IBM Corp., Armonk, NY, USA) and
SAS software (version 9.2, SAS Institute Inc., Cary, NC,
USA).
Results
Baseline characteristics
In general, patients with spinal metastases did not differ from
the entire population of 1157 patients with bone metastases.
Table 1 shows baseline characteristics of the study population
(n, 343). Primary tumors were mainly breast (42%), prostate
(24%), and lung (20%) cancer. The mean age was 65 years
(range 32–89 years) and 52% was male. The majority of pa-
tients was in good to moderate condition; 71% had a KPS of
70 or higher. The mean pain score at baseline was 6.4 (range
2–10). Visceral metastases were documented in 28% of pa-
tients; 55% of patients received concomitant systemic therapy
at the time of randomization.
Two hundred fifty patients (73%) were treated with a single
PA field and 93 patients (27%) with an APPA technique. The
most frequently treated localization was the lumbar spine
(53%), followed by the thoracic spine (34%). The remaining
patients were treated at overlapping regions. Baseline charac-
teristics did not differ between both treatment technique
groups, except for systemic therapy. More patients in the
group treated with a PA field were treated with systemic ther-
apy (59%), compared to patients treated with an APPA tech-
nique (43%, p = 0.009).
At baseline, the mean scores of the individual complaints
items were low, varying from 1 (no complaints) to 2 (minor
complaints), on a scale from 1 to 4. The mean sum score of
abdominal complaints was 1.3 (range 0–7.5, on a scale from 0
to 10) and the mean sum score of skin complaints was 0.7
(range 0–8.3, on a scale from 0 to 10). No baseline differences
in items or sum scores between the two treatment groups were
observed.
A preference per treatment institute was noticed for treat-
ment technique. Institute policy and preferences mainly deter-
mined the choice of technique, instead of individual patient
characteristics.
Pain response
In total, 241 (74%) of the 325 evaluable patients had a pain
response to radiotherapy, with no significant difference be-
tween the two treatment techniques (74% each). The pain
response rate is comparable to that of the entire DBMS
population.
Side effects
Side effects were minor. In general, patients experienced more
abdominal complaints than skin complaints. Four and 8 weeks
after treatment, respectively, 264 (77%) and 229 (67%) pa-
tients returned questionnaires. Figure 1 shows the course of
complaints in the first weeks after treatment. Patients treated
with an APPA technique experienced more abdominal com-
plaints compared to patients treated with a PA field. This dif-
ference was temporary; abdominal complaints were compara-
ble 5 weeks after treatment. Skin complaints increased mini-
mally over time, irrespective of treatment technique (Fig. 1a).
For both techniques, patients receiving multiple fractions ex-
perienced more abdominal complaints than patients receiving
a single fraction (Fig. 1b). Differences in skin complaints were
hardly noticed (Fig. 1c).
In patients treated with both techniques, the course of com-
plaints was similar for all anatomical localizations, although
most outspoken for the lumbar spine in patients treated with
an APPA technique (Fig. 2). For skin complaints, only the two
patients treated at the lumbo-sacral spine with an APPA tech-
nique showed a distinctive increase, to a maximum mean
score of 3.4 (scale of 0–10).
Studying the separate side effects for all 343 patients, a
trend was noticed towards more vomiting and abdominal pain
in patients treated with the APPA technique (p = 0.054 and
p = 0.053, respectively). Patients treated with the APPA tech-
nique had significantly more severe complaints of diarrhea
(p = 0.044). No significant difference was noticed for nausea.
Studying the abdominal side effects for the lower spine (all
patients, excluding those treated on the thoracic spine only),
there were statistically significant differences between treat-
ment techniques. For all studied items (nausea, vomiting, ab-
dominal pain, and diarrhea), patients treated with the APPA
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technique experienced more complaints than patients treated
with the PA technique (p values all <0.009).
Table 2 shows the results of the multivariate analyses.
Treatment schedule and location were independent predictors
for abdominal complaints. Patients treated with a single frac-
tion had a lower risk of abdominal complaints (OR 0.49 (95%
CI 0.29–0.81)) compared to multiple fractions. Patients treat-
ed at the thoraco-lumbar and lumbar spine had a higher risk of
abdominal complaints (OR 2.51 (0.93–6.80) and 2.29 (1.34–
3.93), respectively), compared to radiotherapy of the thoracic
spine. For skin complaints (Table 3), primary tumor and lo-
calization were predictive in multivariate analyses. Patients
with lung cancer (OR 2.27 (1.20–4.30) compared to breast
cancer) had a higher risk of skin complaints. Patients treated
at the lumbo-sacral spine (OR 1.83 (0.52–6.49) compared to
radiotherapy of the thoracic spine) had a higher risk, while
Table 1 Baseline characteristics of patients with painful spinal metastases, treated with a PA or an APPA technique
n Entire cohort Spinal patients PA APPA Difference PA
versus APPAa1157 343 250 93
Primary tumor n.s.
Breast cancer 451 (39%) 145 (42%) 110 (44%) 35 (38%)
Prostate cancer 267 (23%) 83 (24%) 63 (25%) 20 (22%)
Lung cancer 287 (25%) 68 (20%) 48 (19%) 20 (22%)
Other 152 (13%) 47 (14%) 29 (12%) 18 (19%)
Age n.s.
≤ 65 years 565 (49%) 167 (49%) 120 (48%) 47 (51%)
> 65 years 592 (51%) 176 (51%) 130 (52%) 46 (50%)
Gender n.s.
Male 624 (54%) 178 (52%) 125 (50%) 53 (57%)
Female 533 (46%) 165 (48%) 125 (50%) 40 (43%)
KPS n.s.
90–100 221 (19%) 67 (20%) 47 (19%) 20 (22%)
70–80 587 (51%) 176 (51%) 132 (53%) 44 (47%)
20–60 343 (30%) 100 (29%) 71 (28%) 29 (31%)
Pain score n.s.
2–4 234 (20%) 71 (21%) 54 (22%) 17 (18%)
5–7 550 (48%) 155 (45%) 116 (46%) 39 (42%)
8–10 366 (32%) 117 (34%) 80 (32%) 37 (40%)
Visceral metastases n.s.
No 838 (72%) 247 (72%) 178 (71%) 69 (74%)
Yes 319 (28%) 96 (28%) 72 (29%) 24 (26%)
Systemic therapy 0.009
No 531 (46%) 156 (46%) 103 (41%) 53 (57%)
Yes 626 (54%) 187 (55%) 147 (59%) 40 (43%)
Treatment schedule n.s.
1 × 8 Gy 578 (50%) 171 (50%) 129 (52%) 42 (45%)
6 × 4 Gy 579 (50%) 172 (50%) 121 (48%) 51 (55%)
Pain medication n.s.
No opioids 667 (58%) 170 (50%) 123 (49%) 47 (51%)
Opioids 490 (42%) 173 (50%) 127 (51%) 46 (50%)
Spinal localization n.s.
Thoracic spine 117 (34%) 90 (36%) 27 (29%)
Thoraco-lumbar spine 32 (9%) 27 (11%) 5 (5%)
Lumbar spine 183 (53%) 124 (50%) 59 (63%)
Lumbo-sacral spine 11 (3%) 9 (4%) 2 (2%)
PA, Posterior-anterior field; APPA, Anterior-posterior and posterior-anterior field; KPS, Karnofsky performance score; Gy, Gray; n.s., not significant
a Chi-square
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patients treated at the lumbar spine had a lower risk of skin
complaints (OR 0.54 (0.32–0.91)) compared to the thoracic
spine.
Treatment technique did not predict for abdominal or skin
toxicity after radiotherapy. When studying patients per treat-
ment arm, treatment technique was not significantly associat-
ed with abdominal or skin toxicity.
Discussion
This study showed that treatment technique did not predict for
abdominal nor skin complaints. Pain response rates did not
differ between both treatment techniques. In a multivariate
model, fractionation schedule and treated localization were
independent predictors of abdominal complaints. Primary
Fig. 1 The course of complaints
(range of score 0 to 10) after
radiotherapy for painful spinal
metastases. aAbdominal and skin
complaints per treatment
technique. b Abdominal
complaints per treatment
technique and fractionation
schedule. c Skin complaints per
treatment technique and
fractionation schedule
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tumor and treated location appeared to be predictors of skin
complaints.
Although nowadays more conformal techniques and even
stereotactic radiotherapy are frequently used in patients with
painful bone metastases, the benefits of those techniques com-
pared to the conventional techniques still remain to be proven.
All available data show that a dose higher than 8 Gy is not
superior to a single dose of 8 Gy in terms of pain control [20].
These techniques have the disadvantage that they are more
time consuming in terms of preparation, additional imaging
modalities (such as magnetic resonance imaging) needed, and
a more complex and technically demanding treatment plan-
ning [21–23]. Furthermore, they are more expensive than con-
ventional treatment techniques [24] and treatment time is in
general prolonged, which causes more inconvenience for the
patients. Therefore, for the majority of patients, conventional
techniques still remain the treatment of first choice [25].
In general, the reported side effect scores were relatively
low. This does not imply that those side effects are not rele-
vant, since even mild complaints might be burdensome. In a
study among 368 patients receiving radiotherapy, patients
with nausea, although with mild severity in 72% of patients,
had a lower QoL and a lower overall level of well-being than
patients without nausea [26].
Our results showing more abdominal complaints with the
multiple fraction treatment are in line with the results from
Chow et al. in re-irradiated patients with painful bone metas-
tases [27]. They described more vomiting, loss of appetite,
and diarrhea after 20 Gy in multiple fractions compared to a
single fraction of 8 Gy. They also described more redness of
the skin after multiple fractions, which was not noticed in our
analyses, although redness was not specifically questioned.
The abdominal side effects of the APPA technique were
more prominent in patients treated on the lower spine. In this
part of the spine, the vertebrae are located relatively ventral.
An APPA technique gives a better dose coverage, due to the
deep location of the target volume, with the anterior body of
the fifth lumbar vertebra located at a mean depth of 12 cm
[11]. A PA technique might lead to a lower dose on the ventral
part of the vertebral body, which can be a disadvantage, since
previous studies have shown that a dose of 8 Gy results in a
higher pain response rate than lower doses [28, 29]. On the
Fig. 2 The course of abdominal
complaints (range of score 0 to
10) after radiotherapy for painful
spinal metastases. To facilitate
interpretation, subgroups with
less than 10 patients were not
shown in the figure (lumbo-sacral
spine PA (n, 9), thoraco-lumbar
spine APPA (n, 5), lumbo-sacral
spine APPA (n, 2)). a Abdominal
complaints using the PA
technique per location. b
Abdominal complaints using the
APPA technique per location
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other hand, in this study population, the response rate does not
differ between treatment techniques.
Another disadvantage of the PA technique at the lower
spine might be the high skin dose when trying to cover the
Table 2 Analysis of potential
predictors for developing
abdominal complaints within
4 weeks after treatment for painful
spinal metastases
Baseline variables % of patients with Odds ratio (95% CI)
Abdominal complaints UVAa MVAa
Primary tumor
Breast cancer 73% 1.00 #
Prostate cancer 71% 0.90 (0.49–1.67)
Lung cancer 69% 0.84 (0.43–1.64)
Other 64% 0.68 (0.33–1.42)
Age
≤ 65 years 70% 1.00 #
> 65 years 70% 1.01 (0.62–1.64)
Gender
Male 71% 1.00 #
Female 70% 0.95 (0.59–1.54)
KPS
90–100 65% 1.00 #
70–80 73% 1.16 (0.61–2.20)
20–60 70% 0.78 (0.39–1.55)
Pain score
2–4 69% 1.00 #
5–7 73% 1.22 (0.65–2.30)
8–10 68% 0.96 (0.49–1.86)
Visceral metastases
No 69% 1.00 #
Yes 74% 1.26 (0.72–2.22)
Systemic therapy
No 73% 1.00 #
Yes 68% 0.78 (0.48–1.27)
Treatment schedule
6 × 4 Gy 78% 1.00 1.00
1 × 8 Gy 63% 0.49 (0.30–0.81) 0.49 (0.29–0.81)
Pain medication
No opioids 71% 1.00 #
Opioids 70% 0.95 (0.59–1.54)
Spinal localization
Thoracic spine 60% 1.00 1.00
Thoraco-lumbar spine 79% 2.44 (0.91–6.54) 2.51 (0.93–6.80)
Lumbar spine 77% 2.22 (1.31–3.77) 2.29 (1.34–3.93)
Lumbo-sacral spine 45% 0.56 (0.16–1.94) 0.65 (0.18–2.30)
Treatment technique
PA 69% 1.00 #
APPA 75% 1.35 (0.76–2.37)
95%, CI 95% confidence interval; UVA, Univariate analysis; MVA, Multivariable analysis; KPS, Karnofsky
performance status; PA, Posterior-anterior field; APPA, Anterior-posterior and posterior-anterior field
a Logistic regression analysis
#Did not remain in the final model
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ventral part of the vertebral body [11]. We did not notice skin
side effects related to treatment technique, but this might be
due to the type of questions asked and the lack of an objective
physical examination. An option could be to treat this location
with a three-field or intensity-modulated technique, thereby
avoiding bowel structures [30] and the skin [31, 32].
However, these conformal techniques are more time consum-
ing, for patients and logistics [33], and not available in every
Table 3 Analysis of potential
predictors for developing skin
complaints within 4 weeks after
treatment for painful spinal
metastases
Baseline variables % of patients with Odds ratio (95% CI)
Skin complaints UVAa MVAa
Primary tumor
Breast cancer 31% 1.00 1.00
Prostate cancer 28% 0.87 (0.47–1.61) 0.95 (0.50–1.79)
Lung cancer 49% 2.19 (1.17–4.11) 2.27 (1.20–4.30)
Other 36% 1.26 (0.61–2.62) 1.28 (0.61–2.70)
Age
≤ 65 years 39% 1.00 #
> 65 years 30% 0.66 (0.41–1.06)
Gender
Male 35% 1.00 #
Female 33% 0.92 (0.58–1.47)
KPS
90–100 34% 1.00 #
70–80 31% 0.84 (0.46–1.56)
20–60 40% 1.29 (0.66–2.51)
Pain score
2–4 29% 1.00 #
5–7 34% 1.22 (0.65–2.31)
8–10 38% 1.48 (0.76–2.90)
Visceral metastases
No 33% 1.00 #
Yes 38% 1.27 (0.76–2.14)
Systemic therapy
No 38% 1.00 #
Yes 31% 0.75 (0.47–1.20)
Treatment schedule
6 × 4 Gy 31% 1.00 #
1 × 8 Gy 37% 1.34 (0.84–2.15)
Pain medication
No opioids 33% 1.00 #
Opioids 35% 1.09 (0.68–1.75)
Spinal localization
Thoracic spine 42% 1.00 1.00
Thoraco-lumbar spine 39% 0.91 (0.39–2.14) 0.95 (0.40–2.25)
Lumbar spine 27% 0.52 (0.31–0.88) 0.54 (0.32–0.91)
Lumbo-sacral spine 55% 1.69 (0.49–5.89) 1.83 (0.52–6.49)
Treatment technique
PA 33% 1.00 #
APPA 37% 1.19 (0.70–2.02)
95%, CI 95% confidence interval; UV, A univariate analysis; MVA, Multivariable analysis; KPS, Karnofsky
performance status; PA, Posterior-anterior field; APPA, Anterior-posterior and posterior-anterior field
a Logistic regression analysis
#Did not remain in the final model
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institution. A more conformal, but efficient and easy tech-
nique is a single PA field using 10MV, with the addition of a
second AP field, contributing less than 50% of the dose, to
increase the dose ventrally to at least 85% of the prescribed
dose. In this way, side effects to the bowel can be minimized.
In our multivariate analyses, we found that patients with
bone metastases from lung cancer are at increased risk of skin
complaints. We have no reason to believe that those patients
are more sensitive to radiotherapy. We also found that patients
treated at the lumbo-sacral spine have more skin complaints.
An explanation might be the varying depth of lumbal and
sacral vertebra [11], possibly leading to more skin dose when
trying to cover the entire vertebral bodies with a PA field.
However, we believe those skin complaints to be of minor
relevance, due to the limited increase in complaints.
A disadvantage of our analyses is, firstly, that we are not
informed about the intake of anti-emetics and/or anti-
diarrhea medication. It has been shown that the decision
on prescribing medication differs per physician [34], so
patients from some physicians might have had medication
for side effects, while others had not. Secondly, the choice
of treatment technique was not randomized, increasing the
risk of confounding by indication. We did notice a prefer-
ence per treatment institute. Since institute policy and pref-
erences mainly determined the choice of technique, instead
of individual patient characteristics, we also adjusted our
analyses for treatment institute as sensitivity analyses,
which showed similar outcomes. Thirdly, patients reported
their complaints once a week. Perhaps if reported with
smaller intervals, minor but relevant differences in toxicity
would have been noted. Fourthly, only 93 patients were
treated with the APPA technique, with a subgroup of 51
patients treated with six fractions of 4 Gy and 42 patients
with a single fraction of 8 Gy. Finally, no data were known
about dose distribution.
On the other hand, this dataset provides a unique insight in
patients receiving palliative radiotherapy, due to the number of
patients included and the frequency and contents of the pro-
spective patient-reported follow-up. Although our data were
collected from 1996 until 1998, we believe the results present-
ed here are still representative for current patients receiving
palliative radiotherapy for spinal metastases, which is still
delivered mainly using AP and APPA fields. And, while im-
provements in systemic therapy have occurred over the last
years, the most frequently applied treatment for painful bone
metastases is palliative radiotherapy, with a single fraction of
8 Gy as the golden standard [2]. Although medication might
help to prevent the reported side effects [35], we believe it is
better to try to avoid any side effects by using an optimal
treatment technique, especially in this patient group with fre-
quent co-medication and/or systemic therapies.
In conclusion, we advocate the use of a single fraction to
treat patients with painful uncomplicated spinal metastases.
Based on our analysis, when conventional techniques are
used, there is no preference for either a PA or an APPA tech-
nique. If higher total doses are needed, we advise to search for
a more conformal treatment technique to avoid high doses to
the abdomen, specifically when treating the lower spine.
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